Iovance Biotherapeutics, Inc.
IOVA
$2.21
$0.083.51%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -397.63M | -389.92M | -375.36M | -372.18M | -410.00M |
| Total Depreciation and Amortization | 46.37M | 44.83M | 43.75M | 42.59M | 40.62M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.08M | 100.41M | 103.85M | 98.15M | 77.40M |
| Change in Net Operating Assets | -54.95M | -58.72M | -106.63M | -121.54M | -71.68M |
| Cash from Operations | -323.14M | -303.41M | -334.39M | -352.98M | -363.65M |
| Capital Expenditure | -28.68M | -20.13M | -13.11M | -11.07M | -10.43M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | 0.00 | -52.57M | -52.32M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.08M | 24.71M | 44.07M | -32.77M | -130.18M |
| Cash from Investing | 70.40M | 4.59M | 30.96M | -96.41M | -192.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 254.40M | 214.11M | 354.20M | 403.52M | 401.48M |
| Repurchase of Common Stock | -7.49M | -13.31M | -13.80M | -12.86M | -12.16M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 246.91M | 200.81M | 340.40M | 390.66M | 389.32M |
| Foreign Exchange rate Adjustments | -611.00K | 1.32M | 458.00K | -541.00K | 3.66M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.44M | -96.70M | 37.43M | -59.27M | -163.61M |